

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest  
Event Reported): March 26, 2004

ORAGENICS, INC.

-----  
(Exact name of registrant as specified in its charter)

Florida                      000-50614                      59-3410522

-----  
(State or other jurisdiction of (Commission File Number) (IRS Employer  
incorporation or organization) Identification No.)  
-----

12085 Research Drive, Alachua, Florida                      32615

-----  
(Address of principal executive offices)                      (Zip Code)

(386) 418-4018

-----  
(Registrant's telephone number, including area code)

Item 5. Other Events and Regulation FD Disclosure.

On March 29, 2004 the Company issued a press release announcing that warrant holders exercised 83% of the 1,200,000 outstanding Series B warrants prior to their expiration on March 24, 2004. Exercise of 995,400 Series B warrants at the \$3.00 exercise price resulted in a total of \$2,986,200 million (U.S.) received by the Company. A copy of the press release is filed with this report as Exhibit 99.1 and incorporated by reference.

Item 7. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release of the Company dated March 26, 2004.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORAGENICS, INC.

By: /s/ Mento A. Soponis

-----  
Mento A. Soponis  
President, Principal Executive  
Officer and a Member of

the Board of Directors

Dated: March 29, 2004

Contact:  
Mento A. "Chuck" Soponis  
Chief Executive Officer  
Oragenics, Inc.  
(386) 418-4018

FOR IMMEDIATE RELEASE

ORAGENICS WARRANTS EXERCISED

Alachua FL (March 29, 2004) - Oragenics, Inc. (TSX-V: ORA.U; OTC-BB: OGEN) announced today that warrant holders exercised 83% of the 1,200,000 outstanding Series B warrants prior to their expiration on March 24, 2004. Exercise of 995,400 Series B warrants at the \$3.00 exercise price resulted in a total of \$2,986,200 million (U.S.) received by the Company.

"We are appreciative and heartened by the support our shareholders have demonstrated through the exercise of these warrants," stated Chuck Soponis, President & CEO of the company. "The additional capital received by Oragenics will strengthen our ability to move our development projects forward."

The Company has a total of 14,314,630 shares outstanding.

Oragenics, Inc. is an emerging biotechnology research and development company. Located in Alachua, Florida at the University of Florida's Sid Martin Biotechnology Development Incubator, Oragenics is developing three new healthcare products. The most advanced product is an oral rinse for the prevention of tooth decay, which is anticipated to enter clinical trials in 2004. The second product in pre-clinical development is a broad-spectrum antibiotic. Oragenics is also developing a probiotic product to maintain oral health. For more information about Oragenics, please consult the Company's website at [www.oragenics.com](http://www.oragenics.com).

#####

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements which reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe", "expect", "anticipate", "intend", "estimate", "project" and similar expressions which do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to (1) the ability to successfully complete development and commercialization of Oragenics' technologies and products; (2) the ability to obtain substantial additional funding; (3) the ability to develop and commercialize products before competitors; and (4) other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.